You are here

Shionogi

Shionogi starts global Phase II clinical trial of redasemtide

Shionogi starts global Phase II clinical trial of redasemtide

Clinical Trials Arena

clinical trials

Flag link:

Shionogi's COVID-19 antiviral nabs Japanese approval to rival drugs from Pfizer, Merck

Shionogi's COVID-19 antiviral nabs Japanese approval to rival drugs from Pfizer, Merck

Fierce Pharma

Flag link:

Shionogi's COVID-19 vaccine matches Pfizer's Comirnaty in booster trial

Shionogi's COVID-19 vaccine matches Pfizer's Comirnaty in booster trial

Fierce Biotech

Flag link:

Shionogi files for approval of oral COVID-19 antiviral in Japan, brushing off missed clinical endpoint in race to market

Shionogi files for approval of oral COVID-19 antiviral in Japan, brushing off missed clinical endpoint in race to market

Fierce Biotech

Flag link:

Shionogi licenses out 3rd-gen HIV asset to ViiV, notches a flop in chronic cough

Shionogi licenses out 3rd-gen HIV asset to ViiV, notches a flop in chronic cough

Fierce Biotech

ViiV Healthcare

clinical trials

Flag link:

One year after Fetroja approval, Shionogi expands label to include difficult-to-treat pneumonia

One year after Fetroja approval, Shionogi expands label to include difficult-to-treat pneumonia

Endpoints

hospital-acquired pneumonia

ventilator-associated bacterial pneumonia

Flag link:

Biopharma takeovers show quantity, if not quality

Biopharma takeovers show quantity, if not quality

EP Vantage

Gilead Sciences

Portola Pharmaceuticals

Stemline Therapeutics

Tetra Therapeutics

Flag link:

PhII Alzheimer's data looming, Shionogi spending up to $500M on a buyout involving one of the toughest bets in biotech

PhII Alzheimer's data looming, Shionogi spending up to $500M on a buyout involving one of the toughest bets in biotech

Endpoints

Alzheimer's disease

Tetra Therapeutics

Flag link:

Shionogi boosts Tetra Alzheimer's deal, nabs buyout option

Shionogi boosts Tetra Alzheimer's deal, nabs buyout option

Fierce Biotech

Tetra Therapeutics

Flag link:

Roche's Xofluza may give rise to resistant strains, raising fears of a 'worst case scenario'

Roche's Xofluza may give rise to resistant strains, raising fears of a 'worst case scenario'

Endpoints

Flag link:

After positive panel vote, Shionogi antibiotic scores US approval

After positive panel vote, Shionogi antibiotic scores US approval

Endpoints

Flag link:

Despite worries triggered by imbalance of deaths, Shionogi's antibiotic clears FDA panel vote

Despite worries triggered by imbalance of deaths, Shionogi's antibiotic clears FDA panel vote

Endpoints

advisory panels

Flag link:

In-house FDA review flags a suspicious imbalance in deaths as Shionogi hunts an OK for antibiotic

In-house FDA review flags a suspicious imbalance in deaths as Shionogi hunts an OK for antibiotic

Endpoints

advisory panels

Flag link:

Shionogi celebrates antibiotic win in pneumonia just ahead of its date with FDA regulators

Shionogi celebrates antibiotic win in pneumonia just ahead of its date with FDA regulators

Endpoints

nosocomial pneumonia

Flag link:

Two years following US approval, Japan's Shionogi wins EU green light for opioid constipation drug

Two years following US approval, Japan's Shionogi wins EU green light for opioid constipation drug

Endpoints

opioid-induced constipation

Flag link:

FDA Approves First New Flu Drug in Nearly 20 Years

FDA Approves First New Flu Drug in Nearly 20 Years

CP Wire

Flag link:

FDA Approves First New Flu Drug in Nearly 20 Years

Flag link:

Fast-acting flu drug shows strong potential, but clinical trial results also raise concerns

Fast-acting flu drug shows strong potential, but clinical trial results also raise concerns

Stat

clinical trials

baloxavir marboxil

Flag link:

Shire, Shionogi File NDA for Intuniv for Adults in Japan

Shire, Shionogi File NDA for Intuniv for Adults in Japan

Yahoo/Zacks.com

Flag link:

Pages